methyl 2-isopropoxyacetimidate | 98278-14-9

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 甲亚胺酸及其衍生物
• 英文名称: methyl 2-isopropoxyacetimidate
• 英文别名: 2-Isopropyloxy-acetimidsaeure-methylester；Isopropyloxy-acetimidsaeure-methylester；Methyl 2-propan-2-yloxyethanimidate
• CAS: 98278-14-9
• 化学式: C₆H₁₃NO₂
• 分子量: 131.175
• InChiKey: HULAPGQHZWKPSN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.9
• 重原子数：
  9
• 可旋转键数：
  4
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.83
• 拓扑面积：
  42.3
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  methyl 2-isopropoxyacetimidate 在 氨 作用下， 以 乙醇 为溶剂， 反应 48.0h， 生成 4-amino-2-(isopropoxymethyl)pteridine
  参考文献：
  名称：

  Synthesis and potential antiallergic activity of new pteridinones and related compounds

  摘要：

  The synthesis and pharmacological profile of a series of 2-alkoxy and 2-phenoxymethyl-3H-pteridin-4-ones and related compounds are described. These compounds displayed antiallergic activity in the passive cutaneous anaphylaxis test in rats. In contrast to both sodium cromoglycate and nedocromil sodium, many of our compounds were active when administered orally. The most potent in this series, 2-ethoxymethyl-3H-pteridin-4-one 2b (LCB 2183) was investigated in other models of allergy and inflammation. The antiallergic activity was confirmed and interesting antiinflammatory properties were observed. It was therefore selected for further development as a human therapeutic agent.

  DOI：

  10.1016/0223-5234(96)80364-3

文献信息

• US5167949A
  申请人：——

  公开号：US5167949A

  公开（公告）日：1992-12-01
• US5270465A
  申请人：——

  公开号：US5270465A

  公开（公告）日：1993-12-14
• Synthesis and potential antiallergic activity of new pteridinones and related compounds
  作者：G Ferrand、H Dumas、JC Depin、Y Quentin

  DOI：10.1016/0223-5234(96)80364-3

  日期：1996.1

  The synthesis and pharmacological profile of a series of 2-alkoxy and 2-phenoxymethyl-3H-pteridin-4-ones and related compounds are described. These compounds displayed antiallergic activity in the passive cutaneous anaphylaxis test in rats. In contrast to both sodium cromoglycate and nedocromil sodium, many of our compounds were active when administered orally. The most potent in this series, 2-ethoxymethyl-3H-pteridin-4-one 2b (LCB 2183) was investigated in other models of allergy and inflammation. The antiallergic activity was confirmed and interesting antiinflammatory properties were observed. It was therefore selected for further development as a human therapeutic agent.